
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics is poised for success in the rare disease market with its pipeline candidate sparsentan, which is in late-stage development for rare kidney disorders such as FSGS and IgAN. The company has reported strong patient start forms (PSFs) growth for sparsentan, with an average 40% year-over-year increase over the last four quarters, and has also observed a positive market response for its recently approved treatment for FSGS. Travere has established a solid commercial infrastructure and is well-positioned for future growth and execution in this underserved market, making it an attractive investment opportunity for investors.
Bears say
Travere Therapeutics is facing numerous challenges as a company, including a recent missed revenue target for their Filspari drug. Despite potential inflection points in their pipeline, the overall trajectory of patient start forms and PSF numbers are not strong enough to support substantial long-term growth for the company. Additionally, the recent approval of their drug Filspari for FSGS has not resulted in a significant increase in revenue or addressable population, raising concerns about the company's overall growth potential.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares